SCHEMBL7203724

SCHEMBL7203724

CCCNC(=O)NCCC1=COc2ccccc2O1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 7/20 0.72
PABPC1 P11940 1/20 0.43
ALOX15 P16050 1/20 0.43
EPHX1 P07099 2/20 0.39
SCN1A P35498 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
MAPT P10636 3/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7199016 0.86 MTNR1A (0.64) MTNR1ASCN1ASCN2ASCN3AMAPT
SCHEMBL7203743 0.84 MTNR1A (1.00) MTNR1ASCN1ASCN2ASCN3AKMT2A
SCHEMBL5349885 0.83 MTNR1A (0.51) MTNR1APABPC1ALOX15L3MBTL1NPC1
SCHEMBL5338460 0.83 MTNR1A (0.51) MTNR1APABPC1ALOX15EPHX1MAPT
SCHEMBL7854658 0.80 RAB9A (0.49) MTNR1AEPHX1KMT2AGAAHPGD
SCHEMBL6076592 0.79 MTNR1A (0.47) MTNR1APABPC1ALOX15EPHX1MAPT
SCHEMBL7098613 0.74 MTNR1A (0.40) MTNR1AMAPTALDH1A1
SCHEMBL7198985 0.72 MTNR1A (0.73) MTNR1ASCN1ASCN2ASCN3AKMT2A
SCHEMBL6075745 0.71 MTNR1A (0.39) MTNR1APABPC1ALOX15GAAHPGD
SCHEMBL7201865 0.71 MTNR1A (0.52) MTNR1ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
EP-0998471-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 2000-05-10 EP disclosed
WO-1998052935-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 MTNR1A 1/4885PABPC1 4350/4885ALOX15 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.